Rafael Fonseca, MD

Deputy Director, Mayo Clinic Cancer Center
Getz Family Professor of Cancer
Professor of Medicine, Mayo Clinic College of Medicine
Site Director, Hematological Malignancies, Mayo Clinic
Scottsdale, Arizona

Dr. Rafael Fonseca received his medical degree from Universidad Anahuac School of Medicine, Mexico City, Mexico. He continued his postgraduate studies with a residency in internal medicine at the University of Miami, Jackson Memorial Hospital, and a fellowship in clinical hematology and medical oncology at the Mayo Clinic, Rochester, Minnesota. Dr. Fonseca is currently deputy director, Mayo Clinic Cancer Center, Getz Family Professor of Cancer and professor of medicine, Mayo Clinic College of Medicine, as well as site director, hematological malignancies, Mayo Clinic, Scottsdale, Arizona.

Dr. Fonseca is a fellow of the International Society of Hematology and is board certified in internal medicine, medical oncology, and hematology. In addition, he holds professional memberships in the American Association of Cancer Research, American Society of Hematology, American Society of Clinical Oncology, and the Mexican Society of Internal Medicine, among others. Dr. Fonseca is a reviewer for numerous journals including American Journal of Hematology, American Journal of Medicine, Blood, British Journal of Haematology, Circulation, Hematologica, International Journal of Cancer, Journal of Clinical Oncology, Leukemia, New England Journal of Medicine, and is on the editorial board of Molecular Cancer Therapeutics, and Leukemia. He has written more than 100 peer-reviewed articles, book chapters, and abstracts.

Dr. Fonseca has developed an expertise in the management of plasma cell disorders. His clinical practice is primarily composed of patients with multiple myeloma, primary amyloidosis, and monoclonal gammopathy.

Faculty Disclosure
Dr. Rafael Fonseca has received consultant fees from Amgen, Inc. and Celgene Corporation, as well as grant support related to research activities from Celgene, Cylene Pharmaceuticals, and Onyx Pharmaceuticals.

Last modified: March 23, 2021